Company intelligence / Profile preview

HepaTx

Palo Alto, California, USAhepatx.com ↗

Ownership: Private
Employees: ~2
Development stage: Preclinical

Overview

HepaTx develops off-the-shelf allogeneic cell therapies based on adipose-derived stem cells differentiated into hepatocyte-like cells. Their lead candidate aims to treat late-stage liver diseases as an alternative to organ transplant. The company holds exclusive rights to key technology from Stanford University and has entered a collaboration with Mayo Clinic to advance its platform toward clinical trials. Early focus includes both rare/niche indications for rapid approval paths and broader chronic liver diseases. No published human clinical results yet; programs are preclinical/IND-enabling.

Therapeutic areas: GastroenterologyMetabolic DisordersRare Diseases
Modalities: Allogeneic cell therapyRegenerative medicine technologies
Industry: Biotech

Drug pipeline

5 assets

allogenic hepatocyte-like mesenchymal stem cells

4 more assets in the full pipeline.

Request access →

Partnerships

Mayo Clinic (collaboration/licensing agreement for advancing technology into clinical trials)Stanford University (exclusive worldwide license on core IP).

Beyond the preview

Go deeper on HepaTx.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HepaTx.

Explore the full profile